Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo

British Journal of Pharmacology

Volumn 149, Issue 6, 2006, Pages 666-675

  Amat, M ^a   Benjamim, C F ^b,d   Williams, L M ^c   Prats, N ^a   Terricabras, E ^a   Beleta, J ^a   Kunkel, S L ^b   Godessart, N ^a  

^a Almirall Research Center ^*  (Spain)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

CCR1; Chemokines; Collagen induced arthritis; IL 10; Inflammation; J 113863; Rheumatoid arthritis; TNF

Indexed keywords

1 (1 CYCLOOCTEN 1 YLMETHYL) 4 (2,7 DICHLOROXANTHEN 9 YLCARBOXAMIDO) 1 ETHYLPIPERIDINIUM IODIDE; 1 (1 CYCLOOCTENYLMETHYL) 4 (2,7 DICHLOROXANTHEN 9 YLCARBOXAMIDO) 1 ETHYLPIPERIDINIUM IODIDE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; COLLAGEN; ENTEROTOXIN; INTERLEUKIN 10; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADRENALECTOMY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG RECEPTOR BINDING; INFLAMMATORY INFILTRATE; KNOCKOUT MOUSE; LEUKOCYTE MIGRATION INHIBITION; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RECEPTOR BLOCKING; RHEUMATOID ARTHRITIS; SPECIES COMPARISON; STAPHYLOCOCCUS; SYNOVIUM;

ANIMALS; ARTHRITIS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; RECEPTORS, CHEMOKINE; TUMOR NECROSIS FACTOR-ALPHA; XANTHENES;

EID: 33750969668     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706912     Document Type: Article

References (48)

1. Anders H, Belemezova E, Eis S, Segerer S, Vielhauer V, Perez de Lerma G et al. (2004). Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephro 15: 1504-1513.
2. Anders H, Vielhauer V, Frink M, Linde Y, Cohen C, Blattner SM et al. (2002). A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Inves 109: 251-259.
3. Blease K, Mehrad B, Standiford T, Lukacs N, Kunkel S, Chensue S et al. (2000). Airway remodeling is absent in CCR1-/- mice during chronic fungal allergic airway disease. J Immunol 165: 1564-1572.
4. Branger J, Van Den Blink B, Weijer S, Madwed J, Bos C, Gupta A et al. (2002). Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 168: 4070-4077.
5. Carpenter K, Ewing J, Schuh J, Ness T, Kunkel S, Aparici M et al. (2005). Therapeutic targeting of CCR1 attenuates established chronic fungal asthma in mice. Br J Pharmacol 145: 1160-1172.
6. Cheng J, Watson J, Pazoles C, Eskra J, Griffiths R, Cohan V et al. (1997). The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-alpha (TNFalpha) production in mice: effect of adrenalectomy. J Pharmacol Exp Ther 280: 621-626.
7. Chintalacharuvu S, Wang J, Giaconia J, Venkataraman C (2005). An essential role for CCL3 in the development of collagen antibody-induced arthritis. Immunol Lett 100: 202-204.
8. Clemetson K, Clemetson J, Proudfoot A, Power C, Baggiolini M, Wells T (2000). Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 96: 4046-4054.
9. Feldmann M, Brennan F, Williams R, Woody J, Maini R (2004). The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol 18: 59-80.
10. Gao W, Topham P, King J, Smiley S, Csizmadia V, Lu B et al. (2000). Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 105: 35-44.
11. Gao W, Wynn T, Chang Y, Lee E, Broxmeyer H, Cooper S et al. (1997). Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J Exp Med 185: 1959-1968.
12. Garcia-Ramallo E, Marques T, Prats N, Beleta J, Kunkel S, Godessart N (2002). Resident cell chemokine expression serves as the major mechanism for leukocyte recruitment during local inflammation. J Immunol 169: 6467-6473.
13. Gladue R, Tylaska L, Brissette W, Lira P, Kath J, Poss C et al. (2003). CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J Biol Chem 278: 40473-40480.
14. Gladue R, Zwillich S, Clucas A, Brown M (2004). CCR1 antagonists for the treatment of autoimmune diseases. Current Opinion Invest Drugs 5: 499-504.
15. Godessart N (2005). Chemokine receptors: attractive targets for drug discovery. Ann NY Acad Sci 1051: 647-657.
16. Godessart N, Kunkel S (2001). Chemokines in autoimmune disease. Curr Opin Immunol 13: 670-675.
17. Haringman J, Kraan M, Smeets T, Zwinderman K, Tak P (2003). Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis 62: 715-721.
18. Horuk R (2003). Development and evaluation of pharmacological agents targeting chemokine receptors. Methods 29: 369-375.
19. Horuk R, Clayberger C, Krensky A, Wang Z, Grone H, Weber C et al. (2001). A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J Biol Chem 276: 4199-4204.
20. Katschke Jr K, Rottman J, Ruth J, Qin S, Wu L, Larosa G et al. (2001). Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum 44: 1022-1032.
21. Koch A (2005). Chemokines and their receptors: future targets? Arthritis Rheum 52: 710-721.
22. Lawlor K, Campbell I, O'Donnell K, Wu L, Wicks I (2001). Molecular and cellular mediators of interleukin-1-dependent acute inflammatory arthritis. Arthritis Rheum 44: 442-450.
23. Lee S, Brummet M, Shahabuddin S, Woodworth T, Georas S, Leifermann K et al. (2000). Cutaneous injection of human subjects with macrophage inflammatory protein-1 alpha induces significant recruitment of neutrophils and monocytes. J Immunol 164: 3392-3401.
24. Liang M, Mallari C, Rosser M, Ng H, May K, Monahan S et al. (2000a). Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem 275: 19000-19008.
25. Liang M, Rosser M, Ng H, May K, Bauman J, Islam I et al. (2000b). Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor. Eur J Pharmacol 389: 41-49.
26. Menten P, Wuyts A, Van Damme J (2002). Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 13: 455-481.
27. Murphy P, Baggiolini M, Charo I, Hebert C, Horuk R, Matsushima K et al. (2000). International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52: 145-176.
28. Naya A, Saeki T (2001). J-113863. Chemokine CCR1 receptor antagonist. Drugs future 26: 121-127.
29. Naya A, Snaya A, Sagara Y, Ohwaki K, Saeki T, Ichikawa D et al. (2001). Design, synthesis, and discovery of a novel CCR1 antagonist. J Med Chem 44: 1429-1435.
30. Pettipher E, Eskra J, Labasi J (1997). The inhibitory effect of rolipram on TNF-alpha production in mouse blood ex vivo is dependent upon the release of corticosterone and adrenaline. Cytokine 9: 582-586.
31. Plater-Zyberk C, Hoogewerf A, Proudfoot A, Power C, Wells T (1997). Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett 57: 117-120.
32. Proudfoot A, Buser R, Borlat F, Alouani S, Soler D, Offord R et al. (1999). Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J Biol Chem 274: 32478-32485.
33. Revesz L, Bollbuck B, Buhl T, Eder J, Esser R, Feifel R et al. (2005). Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis. Bioorg Med Chem Lett 15: 5160-5164.
34. Rongione A, Kusske A, Ashley S, Reber H, McFadden D 1997)). Interleukin-10 prevents early cytokine release in severe intraabdominal infection and sepsis. J Surg Res 70: 107-112.
35. Ross S, Williams R, Mason L, Mauri C, Marinova-Mutafchieva L, Malfait A et al. (1997). Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 159: 6253-6259.
36. Rottman J, Slavin A, Silva R, Weiner H, Gerard C, Hancock W (2000). Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol 30: 2372-2377.
37. Sabroe I, Peck M, Jan Van Keulen B, Jorritsma A, Simmons G, Clapham P et al. (2000). A small molecule antagonist of chemokine receptors CCR1 and CCR3. J Biol Chem 275: 25985-25992.
38. Schwarz M, Wells T (2002). New therapeutics that modulate chemokine networks. Nature Rev Drug Discovery 1: 347-358.
39. Shahrara S, Proudfoot A, Woods J, Ruth J, Amin M, Park C et al. (2005). Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum 52: 1907-1919.
40. Sozzani S, Luini W, Borsatti A, Polentarutti N, Zhou D, Piemonti L et al. (1997). Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol 159: 1993-2000.
41. Su S, Mukaida N, Wang J, Nomura H, Matsushima K (1996). Preparation of specific polyclonal antibodies to a C-C chemokine receptor, CCR1, and determination of CCR1 expression on various types of leukocytes. J Leukoc Biol 60: 658-666.
42. Terricabras E, Benjamin C, Godessart N (2004). Drug discovery and chemokine receptor antagonists: eppur si muove. Autoimmun Rev 3: 550-556.
43. Thornton S, Duwel L, Boivin G, Ma Y, Hirsch R (1999). Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum 42: 1109-1118.
44. Tokuda A, Itakura M, Onai N, Kimura H, Kuriyama T, Matsushima K (2000). Pivotal role of CCR1-positive leukocytes in bleomycin-induced lung fibrosis in mice. J Immunol 164: 2745-2751.
45. Topham P, Csizmadia V, Soler D, Hines D, Gerard C, Salant D et al. (1999). Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. J Clin Invest 104: 1549-1557.
46. Vielhauer V, Berning E, Eis V, Kretzler M, Segerer S, Strutz F et al. (2004). CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int 66: 2264-2278.
47. Williams L, Feldman M, Maini R (1992). Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89: 9784-9788.
48. Youssef S, Maor G, Wildbaum G, Grabie N, Gour-Lavie A, Karin N (2000). C-C chemine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J Clin Invest 106: 361-371.